DRW Securities’s Regeneron Pharmaceuticals REGN Stock Holding History

DRW Securities’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$405K	Sell	528 -64	-11%	-$49K	0.01%	723
2025 Q4	$450K	Buy	+592	New	+$402K	0.01%	494
2025 Q3	–	Sell	-440	Closed	-$231K	–	1572
2025 Q2	$231K	Buy	+440	New	+$246K	0.01%	883
2024 Q4	–	Sell	-228	Closed	-$240K	–	749
2024 Q3	$240K	Sell	228 -1	-0.4%	-$1.11K	0.01%	482
2024 Q2	$241K	Sell	229 -589	-72%	-$571K	0.01%	442
2024 Q1	$766K	Buy	+818	New	+$778K	0.02%	200
2023 Q4	–	Sell	-477	Closed	-$393K	–	428
2023 Q3	$393K	Buy	+477	New	+$375K	0.01%	243
2022 Q2	–	Sell	-397	Closed	-$277K	–	336
2022 Q1	$277K	Buy	+397	New	+$251K	0.01%	218
2021 Q3	–	Sell	-567	Closed	-$317K	–	357
2021 Q2	$317K	Buy	+567	New	+$287K	0.01%	221
2020 Q2	–	Sell	-520	Closed	-$254K	–	304
2020 Q1	$254K	Buy	+520	New	+$214K	0.01%	226
2018 Q1	–	Sell	-1,080	Closed	-$406K	–	424
2017 Q4	$406K	Buy	+1,080	New	+$437K	0.04%	254

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

DRW Securities's REGN Position: Q1 2026 in Review

DRW Securities reduced its Regeneron Pharmaceuticals (REGN) stake by 11% in Q1 2026, selling an estimated $49K and leaving 528 shares worth $405K. The position accounts for 0.01% of the portfolio, ranked #723.

DRW Securities first reported a position in REGN in Q4 2017 and has held it in 11 quarters since. The position peaked at $766K in Q1 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

DRW Securities held 528 shares of Regeneron Pharmaceuticals worth $405K as of Q1 2026.
DRW Securities sold 64 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $49K.
Regeneron Pharmaceuticals made up 0.01% of DRW Securities's portfolio in Q1 2026, its #723 holding.
DRW Securities first reported a position in Regeneron Pharmaceuticals in Q4 2017 and has held it in 11 quarters since.
DRW Securities's Regeneron Pharmaceuticals position peaked at $766K in Q1 2024.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.